In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant enterobacteriaceae

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3541-3546

  Betts, Jonathan W ^a   Phee, Lynette M ^a,c   Hornsey, Michael ^b   Woodford, Neil ^a,d   Wareham, David W ^a,c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF ROEHAMPTON   (United Kingdom)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; TIGECYCLINE; ANTIINFECTIVE AGENT; BETA LACTAMASE; CARBAPENEM DERIVATIVE; MINOCYCLINE;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CATERPILLAR; CONTROLLED STUDY; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; GALLERIA MELLONELLA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; SERRATIA MARCESCENS; SURVIVAL RATE; ANALOGS AND DERIVATIVES; ANIMAL; ANTIBIOTIC RESISTANCE; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG EFFECTS; ENTEROBACTER; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOTH;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; COLISTIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ENTEROBACTER; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MOTHS;

EID: 84901258521     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02449-14     Document Type: Article

References (32)

1. Wareham DW, Gordon NC, Hornsey M. 2011. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 66:1047-1051. http://dx.doi.org/10.1093/ jac/dkr069.
2. Lavigne JP, Sotto A, Nicolas-Chanoine MH, Bouziges N, Bourg G, Davin-Regil A, Pages JM. 2012. Membrane permeability, a pivotal function involved in antibiotic resistance and virulence in Enterobacter aerogenes clinical isolates. Clin. Microbiol. Infect. 18:539-545. http://dx.doi.org/10. 1111/j.1469-0691.2011.03607.x.
3. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnam P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodword N. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan and the UK: a molecular, biological and epidemiological study. Lancet Infect. Dis. 10:597-602. http://dx.doi.org/10. 1016/S1473-3099(10)70143-2.
4. Carattoli A, Villa L, Poirel L, Bonnin RA, Nordmann P. 2012. Evolution of IncA/C blaCMY-2-carrying plasmids by acquisition of the blaNDM-1 carbapenemase gene. Antimicrob. Agents Chemother. 56:783-786. http://dx.doi.org/10.1128/AAC. 05116-11.
5. Docobo-Perez F, Nordmann P, Dominguez-Herrera J, Lopez-Rojas R, Smani Y, Poirel L, Pachon J. 2012. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. Int. J. Antimicrob. Agents 39: 251-254. http://dx.doi.org/10.1016/j.ijantimicag.2011.10.012.
6. Falagas ME, Karageorgopoulos DE, Nordmann P. 2011. Therapeutic options for infections with Enterobacteriaceae producing carbapenemhydrolyzing enzymes. Future Microbiol. 6:653-666. http://dx.doi.org/10.2217/fmb.11.49.
7. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. 2011. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int. J. Antimicrob. Agents 37:415-419. http://dx.doi.org/10.1016/j.ijantimicag.2011.01.012.
8. Bergen PJ, Li J, Nation RL. 2011. Dosing of colistin-back to basic PK/PD. Curr. Opin. Pharmacol. 11:464-469. http://dx.doi.org/10.1016/j.coph.2011.07. 004.
9. Yahav D, Lador A, Paul M, Leibovici I. 2011. Efficacy and safety of tigecycline: a systematic review and meta-Analysis. J. Antimicrob. Chemother. 66:1963-1971. http://dx.doi.org/10.1093/jac/dkr242.
10. Hornsey M, Ellington MJ, Doumith M, Thomas CP, Gordon NC, Wareham DW, Quinn J, Lolans K, Livermore DM, Woodford N. 2010. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J. Antimicrob. Chemother. 65:1589-1593. http://dx.doi.org/10.1093/jac/dkq218.
11. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. 2005. Evaluation of colistin as an agent against mult-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents 25:11-25. http://dx.doi.org/10.1016/j.ijantimicag.2004.10. 001.
12. Vaara M. 1992. Agents that increase the permeability of the outer membrane. Microbiol. Rev. 56:395-411.
13. Gordon NC, Png K, Wareham DW. 2010. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob. Agents Chemother. 54:5316-5322. http://dx.doi.org/10.1128/AAC.00922-10.
14. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. 2014. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob. Agents Chemother. 58: 654-663. http://dx.doi.org/10.1128/AAC.01222-13.
15. Petrosillo N, Giannella M, Antonelli M, Antonini M, Barsic B, Belancic L, Cadkan Inkaya A, De Pascale G, Grilli E, Tumbarello M, Akova M. 25 November 2013. Colistin-glycopeptide combination in critically ill patients with Gram-negative infection: the clinical experience. Antimicrob. Agents Chemother. http://dx.doi.org/10.1128/AAC.00871-13.
16. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob. Agents Chemother. 56:2108-2113. http://dx.doi.org/10.1128/ AAC.06268-11.
17. Brown SE, Howard A, Kasprzak AB, Gordon KH, East PD. 2009. A peptidomics study reveals the impressive antimicrobial peptide arsenal of the wax moth Galleria mellonella. Insect Biochem. Mol. Biol. 39:792-800. http://dx.doi.org/ 10.1016/j.ibmb.2009.09.004.
18. Champion OL, Cooper IA, James SL, Ford D, Karlyshev A, Wren BW, Duffield M, Oyston PC, Titball RW. 2009. Galleria mellonella as an alternative infection model for Yersinia pseudotuberculosis. Microbiology 155:1516-1522. http://dx.doi.org/10.1099/mic.0.026823-0.
19. Jander G, Rahme LG, Ausubel FM. 2000. Positive correlation between virulence of Pseudomonas aeruginosa mutants in mice and insects. J. Bacteriol. 182:3843-3845. http://dx.doi.org/10.1128/JB.182.13.3843-3845.2000.
20. Hornsey M, Phee L, Stubbings W, Wareham DW. 2013. In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens. Int. J. Antimicrob. Agents 42:343-346. http://dx.doi.org/10.1016/j.ijantimicag.2013.05.010.
21. Wareham DW, Bean DC. 2006. In vitro activities of polymyxin B, imipenem, and rifampin against multi-drug resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50:825-826. http://dx.doi.org/10.1128/AAC.50.2.825-826.2006.
22. Milne KEN, Gould IM. 2010. Combination testing of a multidrugresistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. J. Antimicrob. Chemother. 65:82-90. http://dx.doi.org/10.1093/jac/dkp384.
23. NCCLS. 1999. Methods for determining bactericidal activity of antimicrobial agents, vol. 19, no. 18. Approved guideline M26-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
24. Hornsey M, Wareham DW. 2011. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob. Agents Chemother. 55:3534-3537. http://dx.doi.org/10. 1128/AAC.00230-11.
25. Owen RJ, Li J, Nation RL, Spelman D. 2007. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J. Antimicrob. Chemother. 59:473-477. http://dx.doi.org/10.1093/jac/dkl512.
26. Hindler JA, Humphries RM. 2013. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli. J. Clin. Microbiol. 51:1678-1684. http://dx.doi.org/10.1128/JCM.03385-12.
27. Albur M, Noel A, Bowker K, MacGowen A. 2012. Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 56:3441-3443. http://dx.doi.org/10.1128/AAC.05682-11.
28. Pournaras S, Vironi G, Neou E, Dendrinos J, Dimitroulia E, Poulou A, Tsakris A. 2011. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumonia carbapenemase (KPC)-producing Enterobacteriaceae by time-kill assay. Int. J. Antimicrob. Agents 37:244-247. http://dx.doi.org/10.1016/j.ijantimicag.2010.10.031.
29. Hill L, Veli N, Coote PJ. 2014. Evaluation of Galleria mellonella larvae for measuring the efficacy and pharmacokinetics of antibiotic therapies against Pseudomonas aeruginosa infection. Int. J. Antimicrob. Agents. 43:254-261. http://dx.doi.org/10.1016/j.ijantimicag.2013.11.001.
30. Demirasian H, Dinc G, Ahmed SS, Elmali F, Metan G, Alp E, Doganay M. 25 September 2013. Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination. J. Chemother. http://dx.doi.org/10.1179/ 1973947813Y.0000000143.
31. Mutlu Yilmaz E, Sunbul M, Aksoy A, Yilmaz H, Guney AK, Guvenc T. 2012. Efficacy of tigecycline/colistin combinations in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. Int. J. Antimicrob. Agents 40:332-336. http://dx.doi.org/10.1016/j.ijantimicag.2012.06.003.
32. Michail G, Labrou M, Pitiriga V, Manousaka S, Sakellaridis N, Tskris A, Pournaras S. 2013. Activity of tigecycline in combination with colistin, meropenem, rifampin, or gentamicin against KPC-producing Enterobacteriaceae in a murine thigh model. Antimicrob. Agents Chemother. 57: 6028-6033. http://dx.doi.org/10.1128/AAC.00891-13.